HealthEquity, Inc. $HQY Shares Sold by Wellington Management Group LLP

Wellington Management Group LLP lowered its holdings in HealthEquity, Inc. (NASDAQ:HQY) by 22.0% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 387,894 shares of the company’s stock after selling 109,626 shares during the quarter. Wellington Management Group LLP’s holdings in HealthEquity were worth $35,035,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. BlackRock Inc. purchased a new stake in HealthEquity during the second quarter worth about $1,018,621,000. Wasatch Advisors LP increased its holdings in HealthEquity by 10.5% in the second quarter. Wasatch Advisors LP now owns 7,960,735 shares of the company’s stock valued at $719,014,000 after buying an additional 757,801 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of HealthEquity by 0.3% during the 4th quarter. Geode Capital Management LLC now owns 2,201,232 shares of the company’s stock valued at $201,685,000 after acquiring an additional 5,671 shares during the period. Westfield Capital Management Co. LP boosted its stake in shares of HealthEquity by 13.7% during the 4th quarter. Westfield Capital Management Co. LP now owns 1,952,452 shares of the company’s stock worth $178,864,000 after acquiring an additional 235,794 shares in the last quarter. Finally, William Blair Investment Management LLC purchased a new stake in shares of HealthEquity during the 4th quarter worth approximately $169,956,000. 99.55% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Michael Fiore sold 2,470 shares of the firm’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $95.00, for a total transaction of $234,650.00. Following the sale, the executive vice president owned 56,643 shares in the company, valued at $5,381,085. This trade represents a 4.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Adrian T. Dillon sold 7,632 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $104.61, for a total value of $798,383.52. Following the completion of the sale, the director directly owned 62,395 shares in the company, valued at approximately $6,527,140.95. The trade was a 10.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 12,456 shares of company stock valued at $1,256,664 in the last three months. 1.60% of the stock is currently owned by corporate insiders.

HealthEquity Stock Performance

HealthEquity stock opened at $96.07 on Friday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.99 and a current ratio of 2.99. The stock has a fifty day moving average of $99.37 and a two-hundred day moving average of $88.61. The company has a market capitalization of $7.95 billion, a price-to-earnings ratio of 34.68, a PEG ratio of 1.56 and a beta of 0.22. HealthEquity, Inc. has a fifty-two week low of $72.76 and a fifty-two week high of $107.62.

HealthEquity (NASDAQ:HQY) last released its quarterly earnings results on Thursday, August 27th. The company reported $1.24 earnings per share for the quarter, topping analysts’ consensus estimates of $1.19 by $0.05. HealthEquity had a return on equity of 15.33% and a net margin of 17.36%.The company had revenue of $350.73 million during the quarter, compared to analysts’ expectations of $349.22 million. HealthEquity’s revenue for the quarter was up 95.5% on a year-over-year basis. HealthEquity has set its FY 2027 guidance at 4.660-4.730 EPS. On average, analysts anticipate that HealthEquity, Inc. will post 3.93 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

HQY has been the subject of several research analyst reports. Wall Street Zen downgraded HealthEquity from a “buy” rating to a “hold” rating in a research note on Saturday. Royal Bank Of Canada boosted their target price on HealthEquity from $100.00 to $108.00 and gave the stock an “outperform” rating in a research report on Wednesday, June 3rd. Citigroup reaffirmed a “market outperform” rating on shares of HealthEquity in a research note on Friday, August 28th. Weiss Ratings reiterated a “hold (c+)” rating on shares of HealthEquity in a research report on Wednesday. Finally, Barrington Research reissued an “outperform” rating and issued a $110.00 price objective on shares of HealthEquity in a research note on Friday, May 22nd. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $111.87.

About HealthEquity

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.